The DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Open accessAbstract
BACKGROUND: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. METHODS: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. RESULTS: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. CONCLUSIONS: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“and a single study comparing 2 doses of the direct oral anticoagulant rivaroxaban and aspirin found that anticoagulation was more effective than aspirin without an increase in bleeding rates. 314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Research works printed but not linked: 1
- 2012, MMWR Morb Mortal Wkly Rep, 61, 401
Cited by
Items 201–300 of 786
Tomkowski, W. Z., Kuca, P., Urbanek, T., Chmielewski, D., Krasiński, Z., Pruszczyk, P., Windyga, J., Oszkinis, G., Jawień, A., Burakowski, J., et al. (2017) · Acta Angiologica · doi:10.5603/aa.2017.0008 · Cited by 23
Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis
Chopard, R., Albertsen, I. E., Ecarnot, F., Guth, S., Besutti, M., Falvo, N., Piazza, G., & Meneveau, N. F. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024425 · Cited by 22
Patel, A., Williams, H., Baer, M. R., Zimrin, A. B., & Law, J. Y. (2019) · Acta Haematologica · doi:10.1159/000500223 · Cited by 20
Albertsen, I. E., Søgaard, M., Goldhaber, S. Z., Piazza, G., Skjøth, F., Overvad, T. F., Larsen, T. B., & Nielsen, P. B. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708877 · Cited by 21
Special Considerations in Pulmonary Embolism
Kabrhel, C., Rosovsky, R. P. G., & Garvey, S. R. (2020) · Critical Care Clinics · doi:10.1016/j.ccc.2020.02.008 · Cited by 20
Pompilio, G., Integlia, D., Raffetto, J. D., & Palareti, G. (2020) · TH Open · doi:10.1055/s-0040-1709731 · Cited by 21
Diretrizes sobre trombose venosa profunda da Sociedade Brasileira de Angiologia e Cirurgia Vascular
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301071 · Cited by 27
Weitz, J. I., & Chan, N. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1679906 · Cited by 18
Self-citationEbraheem, M. S., Alzahrani, I., Crowther, M. A., Rochwerg, B. N., & Almakadi, M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14949 · Cited by 22
Lüscher, T. F., Davies, A. J., Beer, J. H., Valgimigli, M., Nienaber, C. A., Camm, A. J., Baumgärtner, I., Diener, H., & Konstantinides, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab642 · Cited by 21
Choice and Duration of Anticoagulation for Venous Thromboembolism
Barnes, G. D., Malik, A., & Ha, N. B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010301 · Cited by 19
Pleiotropic effects of the hemostatic system
Kremers, B., Cate, H. T., & Spronk, H. M. H. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14161 · Cited by 18
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants
Vedovati, M. C., Giustozzi, M., & Becattini, C. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.031 · Cited by 18
Medeiros, S. K., Emery, B., Bhagirath, V. C., Parpia, S., Dwivedi, D. J., Dwivedi, N. J., Kearon, C., & Liaw, P. C. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.11.030 · Cited by 20
Stroke Prevention: Little-Known and Neglected Aspects
Azarpazhooh, M. R., Bogiatzi, C., & Spence, J. D. (2021) · Cerebrovascular Diseases · doi:10.1159/000515829 · Cited by 18
Li, M., Li, J., Wang, X., Xu, H., Wang, Q., Xie, S., Yan, P., Tian, J., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub3 · Cited by 26
Liu, S., Shen, Y., Chen, J., Ruan, Z., Li, H., Wang, K., Xi, X., & Mao, J. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101302 · Cited by 19
Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population
Raskob, G. E., Wendelboe, A. M., Campbell, J. E., Ford, L., Ding, K., Bratzler, D. W., McCumber, M. D., Adamski, A., Abe, K., Beckman, M. G., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15818 · Cited by 20
Talerico, R., Pola, R., Klok, F. A., & Huisman, M. V. (2024) · TH Open · doi:10.1055/s-0043-1776989 · Cited by 20
May, J. E., & Moll, S. (2024) · Blood · doi:10.1182/blood.2023021638 · Cited by 20
The year in cardiology: aorta and peripheral circulation
Heiß, C., Pitcher, A., Belch, J. J. F., Carlo, M. D., Reinecke, H., Baumgärtner, I., Mazzolai, L., & Aboyans, V. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz939 · Cited by 17
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.426 · Cited by 17
Haas, S. K., Mantovani, L. G., Kreutz, R. H., Monje, D., Schneider, J., Zell, E. R., Tamm, M., Gebel, M., Bugge, J., Ageno, W., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12489 · Cited by 17
Hendriks, T., McGregor, S., Rakesh, S., Robinson, J., Ho, K. M., & Baker, R. I. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234048 · Cited by 17
Okumura, Y., Fukuda, I., Nakamura, M., Yamada, N., Takayama, M., Maeda, H., Yamashita, T., Ikeda, T., Mo, M., Yamazaki, T., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020286 · Cited by 18
Su, X., Yan, B., Wang, L., Cheng, H., & Chen, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-048619 · Cited by 17
Khan, F. A., Coyle, D., Thavorn, K., van Katwyk, S., Tritschler, T., Hutton, B., Gal, G. L., Rodger, M. A., & Fergusson, D. A. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3559 · Cited by 17
Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk
King, H., Kelley, T. P., & Shatzel, J. J. (2024) · Hematology · doi:10.1182/hematology.2024000592 · Cited by 16
Pulmonary embolism: Care standards in 2018
Borohovitz, A., Weinberg, M. D., & Weinberg, I. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.005 · Cited by 16
Hypercoagulable States and Thrombophilias: Risks Relating to Recurrent Venous Thromboembolism
Rybstein, M. D., & DeSancho, M. T. (2018) · Seminars in Interventional Radiology · doi:10.1055/s-0038-1642037 · Cited by 20
Predicting the risk of recurrent venous thrombosis: What the future might bring
Lijfering, W. M., Timp, J. F., & Cannegieter, S. C. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14534 · Cited by 19
Papakonstantinou, P. Ε., Tsioufis, C. P., Konstantinidis, D., Iliakis, P., Leontsinis, I., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200420150517 · Cited by 17
Recent advances in understanding, diagnosing and treating venous thrombosis
Chan, N., & Weitz, J. I. (2020) · F1000Research · doi:10.12688/f1000research.27115.1 · Cited by 16
Self-citationState-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism
Goldin, M., Koulas, I., Weitz, J. I., & Spyropoulos, A. C. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1778-1083 · Cited by 17
Self-citationReview of Therapeutic Options for the Prevention of VTE in Total Joint Arthroplasty
Etscheidt, J., Shahien, A. A., Gainey, M., Kronenfeld, D. S., Niu, R., Freccero, D. M., & Smith, E. L. (2020) · Geriatrics · doi:10.3390/geriatrics5010018 · Cited by 15
Bikdeli, B., Hogan, H., Morrison, R. B., Fanikos, J. R., Campia, U., Barns, B. M., Pfeferman, M. B., Snyder, J. E., Khairani, C. D., Goldhaber, S. Z., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1646-2244 · Cited by 16
Challenging clinical scenarios for therapeutic anticoagulation: A practical approach
Martens, K. L., Dekker, S. E., Crowe, M. E., DeLoughery, T. G., & Shatzel, J. J. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.08.015 · Cited by 15
Yoshioka, H., Sato, H., Hatakeyama, H., & Hisaka, A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017013805 · Cited by 15
Weir, M. R., & Kreutz, R. H. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.06.018 · Cited by 16
Nazha, B., Pandya, B., Spyropoulos, A. C., & Kessler, C. M. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1673690 · Cited by 16
Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Khachatryan, T., Hauschild, C., Hoff, J., Contractor, T. A., Khachatryan, A., Tran, H. N., Matsuo, B., Jacobson, A. K., & Hilliard, A. A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00344-6 · Cited by 15
ESC-Leitlinien 2019 zu Diagnostik und Management der akuten Lungenembolie
Osteresch, R., Fach, A., Hambrecht, R., & Wienbergen, H. (2019) · Herz · doi:10.1007/s00059-019-04863-5 · Cited by 15
Sagris, D., Leventis, I., Georgiopoulos, G. A., Korompoki, E., Makaritsis, K. P., Vemmos, K. N., Milionis, H. J., Lip, G. Y. H., & Ntaios, G. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.001 · Cited by 15
Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
Wallvik, N., Renlund, H., & Själander, A. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02319-w · Cited by 16
Mavromanoli, A. C., Barco, S., & Konstantinides, S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12509 · Cited by 15
Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
Chen, X., Huang, W., Sun, A., Wang, L., Mo, F., & Guo, W. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00322-6 · Cited by 16
Pan, L., Wang, M., Zhou, D., Ding, Y., Ji, X., & Meng, R. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02595-0 · Cited by 16
the COMMAND VTE Registry Investigators, Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1791-2 · Cited by 16
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations
Ashton, V., Mudarris, L., & Moore, K. T. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00434-w · Cited by 15
Venous thromboembolism: current management
Stevens, H., Tran, H. A., & Gibbs, H. H. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.039 · Cited by 14
Ткачева, О. Н., Vorobyeva, N. M., Kotovskaya, Y. V., Рунихина, Н. К., Strazhesko, I. D., Вадимовна, В. С., Drapkina, O. M., Komarov, A. L., Orlova, Y. A., Панченко, Е. П., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2847 · Cited by 15
Adamantidi, T., Pisioti, M. S., Pitsouni, S., Maria, C., Georgios, K., Dania, V., Vordos, N., Krokidis, X., & Τσούπρας, Α. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040291 · Cited by 15
Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism
Lim, H. Y., Nandurkar, H. H., & Ho, P. W. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1637750 · Cited by 15
The prevention of venous thromboembolism recurrence in the elderly: a still open issue
Palareti, G., & Poli, D. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1526667 · Cited by 14
Żuk, J., Papuga-Szela, E., Zaręba, L., & Undas, A. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03012-7 · Cited by 16
Antonucci, E., Migliaccio, L., Abbattista, M., Caronna, A., Marchi, S. D., Giorgio, A. D., Giulio, R. D., Lerede, T., Garzia, M., Martinelli, I., et al. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620945792 · Cited by 14
Shen, Q., Chen, Q., Liu, Y., Xue, X., Shen, X., He, Q., Wang, G., & Han, F. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.2007268 · Cited by 14
der Linden, L. R. V., Vanassche, T., Cutsem, E. V., Aelst, L. N. L. V., & Verhamme, P. B. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15785 · Cited by 16
Self-citationBenefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
Prandoni, P., Lensing, A. W. A., Prins, M. H., Gebel, M., Pap, A. F., Homering, M., Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Cohen, A. T., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.009 · Cited by 14
Self-citationBoonyawat, K., Lensing, A. W. A., Prins, M. H., Beyer‐Westendorf, J., Prandoni, P., Martinelli, I., Middeldorp, S., Pap, A. F., Weitz, J. I., & Crowther, M. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12474 · Cited by 14
Self-citationRecent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism
Singh, S., Kumar, P., Yadav, S. K., Jaffer, F. A., & Reed, G. L. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.12.004 · Cited by 13
Pallazola, V. A., Kapoor, R. K., Kapoor, K., McEvoy, J. W., Blumenthal, R. S., & Gluckman, T. J. (2019) · Vascular Medicine · doi:10.1177/1358863x18819816 · Cited by 14
Assessment of a Pharmacist-Led Direct Oral Anticoagulant Monitoring Clinic
Haché, J., Bonsu, K. O., Chitsike, R. S., Nguyen, H. V., & Young, S. W. (2021) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v74i1.3035 · Cited by 13
Khan, F. A., Rahman, A. A., Tritschler, T., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Becattini, C., Agnelli, G., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1690-8728 · Cited by 18
Self-citationZhao, M., Zhang, Q., Wang, X., Zhang, Q., Tian, C., Li, R., Jia, X., Gu, M., & Yang, L. (2021) · Clinical and Translational Science · doi:10.1111/cts.13205 · Cited by 13
Diagnostik und Therapie der Lungenembolie
Konstantinides, S., Mavromanoli, A. C., & Hobohm, L. (2021) · Herz · doi:10.1007/s00059-021-05078-3 · Cited by 14
Update on diagnosis and anticoagulant therapy for venous thromboembolism
Stevens, H., & Tran, H. A. (2018) · Internal Medicine Journal · doi:10.1111/imj.14063 · Cited by 13
Management of Venous Thromboembolisms: Part II. The Consensus for Pulmonary Embolism and Updates.
Wang, K.-L., Kao, Y., Chang, W., Chang, H., Huang, W. C., Hsu, P., Hsu, C., Huang, C.-L., Hsieh, L., Wang, C.-Y., et al. (2020) · PubMed · doi:10.6515/acs.202011_36(6).20200917a · Cited by 15
Anticoagulation in patients with Embolic Stroke of Unknown Source
Spence, J. D. (2019) · International Journal of Stroke · doi:10.1177/1747493019826363 · Cited by 12
An Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Djulbegovic, M., & Lee, A. I. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.010 · Cited by 12
Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban
Moore, K. T., Wong, P., Zhang, L., Pan, G., & Foody, J. M. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1492374 · Cited by 12
Prophylactic anticoagulants for non-hospitalised people with COVID-19
Santos, B. C., Flumignan, R. L., Civile, V. T., Atallah, Á. N., & Nakano, L. C. U. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015102.pub2 · Cited by 18
Lobastov, K. V., Ryzhkin, V., Vorontsova, A., Schastlivtsev, I., Barinov, V., Laberko, L. A., & Rodoman, G. V. (2018) · International Angiology · doi:10.23736/s0392-9590.18.03997-4 · Cited by 13
Agrawal, V., & Kim, E. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1111-2 · Cited by 13
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid
Bejjani, A., & Bikdeli, B. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2451-4014 · Cited by 17
Ramacciotti, E., & Weitz, J. I. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.09.033 · Cited by 11
Self-citationJoyce, E. V., Haymart, B., Kong, X., Ali, M. A., Carrigan, M., Kaatz, S. S., Shah, V. I., Kline-Rogers, E. M., Kozłowski, J., Froehlich, J. B., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025471 · Cited by 11
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
Weitz, J. I., & Khorana, A. A. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-09-0681 · Cited by 11
Self-citationXie, J., Jiang, M., Lin, Y., Deng, H., Xie, X., & Li, L. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1693460 · Cited by 11
Palareti, G., Bignamini, A. A., Cini, M., Li, Y.-J., Urbanek, T., Maďarič, J., Bouslama, K., Юрьевич, С. Г., Andreozzi, G. M., Matuška, J., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02765-1 · Cited by 11
Risk factors for recurrent venous thromboembolism: a real-world analysis
Fu, A. Z., Feng, X., Ashton, V., & Kharat, A. A. (2022) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001140 · Cited by 10
Provoked vs minimally provoked vs unprovoked VTE: does it matter?
Becattini, C., & Cimini, L. A. (2023) · Hematology · doi:10.1182/hematology.2023000492 · Cited by 10
Anticoagulation in the Management of Acute Pulmonary Embolism—A Review
del Toro-Mijares, R., Murguía, A. R., Porres‐Aguilar, M., & Mukherjee, D. (2024) · International Journal of Angiology · doi:10.1055/s-0044-1782537 · Cited by 4
Imberti, D., Pomero, F., & Mastroiacovo, D. (2020) · Blood transfusion · doi:10.2450/2019.0265-18 · Cited by 10
George, C., Rahman, M., & Monagle, P. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00403-5 · Cited by 10
Management of venous thromboembolism in athletes
Swan, D., Carter‐Brzezinski, L., & Thachil, J. V. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100780 · Cited by 10
Ameku, K., & Higa, M. (2018) · Case Reports in Hematology · doi:10.1155/2018/5217301 · Cited by 10
Zhang, C., Xu, B., Liang, G., Zeng, X., Chen, Y., Zhang, F., Wan, Z., Yu, W., Chen, D., Ge, Z., et al. (2018) · Journal of International Medical Research · doi:10.1177/0300060518762281 · Cited by 10
Coleman, C. I., Turpie, A. G. G., Bunz, T. J., & Beyer‐Westendorf, J. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1695-1 · Cited by 10
Self-citationPulmonary Embolism: Contemporary Medical Management and Future Perspectives
Barco, S., & Konstantinides, S. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.18-00054 · Cited by 12
Cappato, R., Chiarito, M., Giustozzi, M., Briani, M., Ali, H., Riva, L., Bonitta, G., Lodigiani, C., Furlanello, F., Balla, C., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.09.007 · Cited by 10
Liu, Z., Zhang, H., Ma, L., Mu, G., Xie, Q., Zhou, S., Wang, Z., Wang, Z., Hu, K., Xiang, Q., et al. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02550-8 · Cited by 11
Anticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.439 · Cited by 11
Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?
Mikler, J., Samoš, M., Bolek, T., Škorňová, I., Stančiaková, L., Staško, J., & Mokáň, M. (2019) · Pediatric Cardiology · doi:10.1007/s00246-019-02159-3 · Cited by 10
Cruz, I. E., Ferreira, P. C., Silva, R. D. M., Silva, F., & Madruga, I. (2019) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2019_001310 · Cited by 10
Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine
Pfrepper, C. (2020) · Visceral Medicine · doi:10.1159/000509150 · Cited by 10
Wang, Y., Shi, Z., Sun, Y., Xue-ying, W., Li, S., Dong, S., & Lan, T. (2020) · Designed Monomers & Polymers · doi:10.1080/15685551.2020.1837442 · Cited by 10
Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
Attard, L. M., Gatt, A., Bertoletti, L., Delluc, A., & Riva, N. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s271411 · Cited by 10
Weiß, L., Uhrig, W., Kelliher, S., Szklanna, P. B., Prendiville, T., Comer, S. P., Edebiri, O., Egan, K., Lennon, Á., Kevane, B., et al. (2024) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202300014 · Cited by 9
Anticoagulation and compression therapy for proximal acute deep vein thrombosis
Palareti, G., Santagata, D., Ponti, C. D., Ageno, W., & Prandoni, P. (2024) · VASA · doi:10.1024/0301-1526/a001138 · Cited by 9
Self-citation
Metadata
- Authors
- Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., & Prandoni, P.
- Affiliations
- University of Ottawa (CA)
- University of Geneva (CH)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-30
- Volume
- 376
- Issue
- 13
- Pages
- 1211-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2595086780
- Cited by
- 787
- References
- 32
- Citations by year
- 2026: 58 · 2025: 77 · 2024: 65 · 2023: 49 · 2022: 78 · 2021: 97 · 2020: 92 · 2019: 96 · 2018: 123 · 2017: 50
- FWCI
- 104.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Ionis Pharmaceuticals
- Janssen Scientific Affairs
- Novo Nordisk
- Novo Nordisk Fonden (NNF12OC1015957)
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, rivaroxaban, aspirin, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, low-dose rivaroxaban, thromboprophylaxis, direct oral anticoagulants, adverse events, dose comparison, post-thrombotic syndrome
- MeSH terms
- Rivaroxaban, Adult, Aged, Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Kaplan-Meier Estimate, Venous Thromboembolism, Secondary Prevention, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.